EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study

Shun Lu, Lin Wu, Qiming Wang, Ziping Wang, Dongqing Lv, Rui Ma, Bo Zhu, Ngoc van Tran, Liyan Jiang, Kejun Nan, Konstantin Laktionov, Stephen Clarke und 5 weitere

Journal of Thoracic Oncology · 2025-03 · 20 (3) · 366-382

DOI: 10.1016/j.jtho.2024.10.024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Thoracic Oncology, 2025-03. Verfasst von Shun Lu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Lung Cancer Centre, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, B7-H1 Antigen. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AstraZeneca, AstraZeneca UK Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: PEARL (NCT03003962) is an open-label, phase 3 study comparing first-line durvalumab monotherapy with chemotherapy in patients with metastatic NSCLC (mNSCLC [EGFR/ALK wild type]) with programmed cell death ligand 1 (PD-L1) tumor cell (TC) membrane expression status of 25% or higher. We report the final analysis of PEARL. METHODS: Adults (N = 669) with previously untreated stage IV mNSCLC were randomized (1:1) to durvalumab 20 mg/kg every four weeks or chemotherapy every three weeks for four to six cycles. The dual primary endpoints were overall survival (OS) in the population with PD-L1 TC of 25% or higher and OS in the population at low risk of early mortality (LREM) with PD-L1 TC of 25% or higher. RESULTS: Durvalumab was associated with a numerical reduction in the risk of death versus chemotherapy in the 25% and higher PD-L1 TC population (OS hazard ratio [HR] = 0.84, 95% confidence interval [CI]: 0.71-0.99, p = 0.037; median OS 14.6 months, 95% CI: 12.2-16.9 versus 12.8 months, 95% CI: 10.1-14.7, respectively). In the 25% and higher PD-L1 TC low risk of early mortality population the OS hazard ratio for durvalumab versus chemotherapy was 0.96 (95% CI: 0.79-1.15, p = 0.628); median OS 14.6 months (95% CI: 12.6-17.2) versus 15.0 months (95% CI: 13.1-16.8), respectively. In the safety population, the incidence of grade 3 or 4 treatment-related adverse events was 15.5% (durvalumab) and 45.9% (chemotherapy). CONCLUSIONS: Durvalumab did not statistically significantly improve OS versus chemotherapy as first-line treatment in patients with mNSCLC and 25% and higher PD-L1 TC. The numerical improvement in OS was consistent with previous studies of first-line immune checkpoint inhibitor monotherapy in patients with mNSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntibodies, MonoclonalB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansFemaleMaleMiddle AgedAgedAdultSurvival RateFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

DurvalumabPD-L1PEARLchemotherapymetastatic NSCLC

Substanzen

durvalumabAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Shanghai Lung Cancer Centre, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
  • The Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, People's Republic of China.
  • Department of Internal Medicine, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, People's Republic of China.
  • The First Department of Thoracic Oncology, Beijing Cancer Hospital, Beijing, People's Republic of China.
  • Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, People's Republic of China.
  • Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, People's Republic of China.

Förderung

  • AstraZeneca
  • AstraZeneca UK Limited

Zitieren

APA

Lu, S., Wu, L., Wang, Q., Wang, Z., Lv, D., Ma, R., Zhu, B., van Tran, N., Jiang, L., Nan, K., Laktionov, K., Clarke, S., Song, M., Mann, H., Liu, Y., Shi, X., & Wu, Y. L. (2025). Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. Journal of Thoracic Oncology, 20(3), 366-382. https://doi.org/10.1016/j.jtho.2024.10.024

Vancouver

Lu S, Wu L, Wang Q, Wang Z, Lv D, Ma R, et al. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. Journal of Thoracic Oncology. 2025;20(3):366-382. doi:10.1016/j.jtho.2024.10.024

BibTeX
@article{Lu2025,
  author = {Lu, Shun and Wu, Lin and Wang, Qiming and Wang, Ziping and Lv, Dongqing and Ma, Rui and Zhu, Bo and van Tran, Ngoc and Jiang, Liyan and Nan, Kejun and Laktionov, Konstantin and Clarke, Stephen and Song, Minghao and Mann, Helen and Liu, Yinglei and Shi, Xiaojin and Wu, Yi-Long},
  title = {Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study},
  journal = {Journal of Thoracic Oncology},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {366--382},
  doi = {10.1016/j.jtho.2024.10.024}
}
Kostenlos starten →